Howmedica Triathlon Hinge Femoral Prep Tray Recall Z-0166-2027 Case Study

Why this case matters

Recall records for surgical instrumentation rarely attract the attention that implant recalls do, but they sit at the same point in the care pathway. A sterile tray is opened in an operating room, which is the moment at which the adequacy of its packaging stops being a compliance question and becomes a clinical one. The Howmedica Osteonics Triathlon Hinge Femoral Prep Tray, catalog 6543-6-514, was recalled under recall number Z-0166-2027 as a Class II matter over residual moisture persisting after a 30 minute dry time in blue wrap. The classification and the recall number are what the supplied record shows; the underlying enforcement database entry itself is not among the documents provided, so the descriptive detail available here is limited to what surrounds the recall rather than to the entry that carries it.

That gap is itself instructive for anyone reading recall data to understand litigation posture. A Class II designation is a regulatory severity assignment, not a finding of injury, and it is not a judicial determination of anything. Cases built around packaging and sterilization failures tend to turn on whether a compromised sterile barrier actually led to a patient exposure, and then on whether that exposure produced a treated infection. The public recall record does not answer either question. It records the firm’s action and the agency’s classification, and it leaves the clinical and legal questions open.

The matter also illustrates how quickly a packaging observation can be restated as a liability theory. Moisture inside a sterile barrier is a process and validation subject. Whether any particular patient’s infection is attributable to that moisture is a different question, requiring organism matching, device and lot tracing, and a timeline. The documents supplied for this case study contain nothing that performs that work, and the analysis below is confined to what they do contain.

The official record

The regulatory record here consists of a recall initiated by Howmedica Osteonics and assigned recall number Z-0166-2027, classified Class II and described in the case materials as ongoing. The recall concerned the Triathlon Hinge Femoral Prep Tray, catalog 6543-6-514. The stated basis was residual moisture following a 30 minute dry time in blue wrap, which is a packaging and sterilization-workflow condition rather than an allegation about the instrument’s design or its performance in bone preparation.

Class II is a middle-tier classification in the agency’s scheme for device recalls. It is the category used where the probability of serious adverse health consequences is characterized as remote rather than probable. That characterization is important context for a retrospective: it tells a reader how the agency weighed the population-level concern at the time of classification, and it does not tell a reader what happened to any individual patient.

The supplied documents do not include the enforcement report entry for this recall. As a result, the record available for this analysis does not state a product quantity, does not state a distribution pattern, does not state an initiation date, and does not state a termination date beyond the “ongoing” status reflected in the case materials. Where the balance of this case study refers to those fields, it does so to note their absence rather than to characterize them.

One further limitation deserves emphasis. The documents supplied include general agency database pages, a Federal Register agency index, federal court statistical pages, and unrelated openFDA records concerning other firms and food products. None of them supplies a court filing, a docket number, a complaint, a settlement, a verdict, or a judicial finding connected to this recall. No civil action is documented in the material provided.

What the documents establish

Three things are established, and no more. First, a recall exists under the number Z-0166-2027, initiated by Howmedica Osteonics, covering the Triathlon Hinge Femoral Prep Tray, catalog 6543-6-514. Second, the agency classified it Class II. Third, the stated reason for the recall was residual moisture after a 30 minute dry time in blue wrap, and the matter is described as ongoing. Every one of these is a fact about a regulatory action.

What the documents do not establish is equally specific, and worth listing because these are the points readers most often assume. There is no documented injury, no documented infection, and no reported patient outcome of any kind. There is no litigation: no plaintiff, no defendant other than the recalling firm as a regulatory actor, no forum, and no procedural posture. There is no admitted fact. A recall initiation reflects a firm’s decision to act and the agency’s classification of that action; it is not an admission of defect, and nothing in the supplied record converts the moisture observation into an adjudicated finding.

The documents also do not establish a causal link between the packaging condition and any clinical event. That link is the core of any product liability theory in a sterile-barrier case, and the public recall record does not attempt it. The general warning language that appears in agency database disclaimers, describing possible consequences ranging from no injury to localized infection to more serious infection requiring medical treatment, antimicrobial therapy, procedural intervention, or hospitalization, is background guidance about sterile barrier compromise as a category. It is not a statement about this recall, and it should not be read as a report of what occurred.

Readers should also note that the classification date, the report date, and the termination date for this recall are not available in the supplied material. Those fields matter for limitation analysis in any eventual claim, and their absence from the record reviewed here means this case study cannot speak to timing at all.

How a claim of this kind is assessed

Matters arising from a sterile barrier failure are assessed along a chain, and each link can independently end the inquiry. The first is packaging validation: whether the tray system, as configured and as wrapped in the specified material, was validated to dry within the labeled time under the conditions used. Moisture after a defined dry time points to a question about that validation rather than to a question about the instrument. The second is whether the barrier was actually compromised in a given instance, which is a lot-level and unit-level question answered by packaging records, inspection findings, and the recall’s own scope.

The third link is exposure and outcome. A patient must have been treated with an affected unit, and the clinical event must be consistent with contamination from that unit. That is where organism identification, culture results, and the surgical timeline become decisive. Infections after orthopedic procedures have multiple possible sources, and distinguishing among them is a matter of clinical evidence, not inference from a recall notice.

The fourth link is the legal one. Product liability in this area ordinarily turns on whether the product reached the patient in a defective condition and whether that condition caused harm. A regulatory classification is evidence that can be used in that analysis, but it is neither necessary nor sufficient to establish liability. Class II status in particular signals the agency’s view that serious harm was remote, which cuts against, though does not foreclose, a serious-injury claim. Where a firm has acted promptly on a packaging concern, that conduct is frequently part of the defense narrative as well.

Finally, aggregation matters. Where a recall affects a defined set of lots and a defined set of hospitals, claims tend to be few and fact-specific rather than numerous and generic. That structure affects how counsel evaluate them, how discovery is scoped, and how any resolution is shaped. The supplied documents do not indicate that any aggregation has occurred here.

What to check before relying on any figure

The most important check is a simple one: confirm that a figure is actually in a record before repeating it. For this recall, the supplied documents state no product quantity, no number of affected units, no number of patients, no number of infections, no settlement amount, and no compensation figure. Any such number encountered elsewhere should be traced to a primary document, and if no primary document supports it, it should be treated as unsupported.

The second check is status. A recall described as ongoing can change classification, scope, or status as the agency completes its review. Reaching a conclusion from a snapshot of an in-progress regulatory action carries a real chance of stating something that is no longer accurate. The record reviewed here reflects an ongoing matter, and later records may differ.

The third check is the distinction between regulatory and civil records. A recall number is not a docket number. A classification is not a finding of liability. A stated reason for recall is the firm’s characterization of a packaging condition as recorded by the agency, not an adjudicated fact. Readers moving between the two kinds of record should keep the boundary visible in their own writing.

The fourth check concerns sources. The database material supplied with this case study carries explicit warnings that its contents are unvalidated and should not be used to make medical care decisions. That warning applies with equal force to legal analysis: an unvalidated database field is a starting point for verification against the underlying enforcement report, the firm’s own notices, and any court record, not a conclusion. On the documents reviewed here, the verified core is narrow, and the honest description of this matter is a Class II packaging recall that remains open, with no documented injury, no documented litigation, and no figure of any kind in the public record supplied.

Sources

• U.S. Food and Drug Administration
• U.S. Food and Drug Administration
• U.S. Food and Drug Administration
• 510(k) Premarket Notification
• Federal Register :: Agencies - Food and Drug Administration
• U.S. Food and Drug Administration
• Data & News